Authors
Bingyan Shen, Yu Zhang, Xia Ou, Zhiqiao Liu, Yue Chen
Published in
Clinical nuclear medicine. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
A 64-year-old man with treatment-emergent neuroendocrine prostate cancer underwent multitracer PET/CT, which demonstrated low somatostatin receptor expression but marked prostate-specific membrane antigen expression in multiple systemic lesions, including a protruding right abdominal wall metastasis. The patient subsequently received [177Lu]Lu-prostate-specific membrane antigen radioligand therapy combined with olaparib. Follow-up PET/CT showed marked reductions in tracer uptake and tumor burden, accompanied by normalization of the neuron-specific enolase level.
PMID:
43019224
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0